Cytomegaloviruses (CMVs) are large, complex pathogens that persistently and systemically colonize most mammals. Human cytomegalovirus (HCMV) causes congenital harm, and has proved hard to control. One problem is that key vaccine targetsvirus entry and spread in naive hosts -remain ill-defined. As CMVs predate human speciation, those of other mammals can provide new insight. Murine CMV (MCMV) enters new hosts via olfactory neurons. Like HCMV it binds to heparan, which is lacking from most differentiated apical epithelia but is displayed on olfactory neuronal cilia. It then spreads via infected dendritic cells (DCs), which migrate to draining lymph nodes (LNs), rejoin the circulation by entering high endothelial venules (HEVs), and extravasate into other tissues. This migration depends quantitatively on M33, a constitutively active viral G protein-coupled receptor (GPCR). The homologous US28 GPCR of HCMV can substitute for M33 in allowing MCMV-infected DCs to leave LNs via HEVs, so HCMV could potentially use the same route. The capacity of DCs to seed MCMV to tissues, and for other DCs to collect it for redistribution, suggest that DC recirculation chronically maintains and links diverse CMV reservoirs through lytic exchange.
INTRODUCTION
Human CMV (HCMV) persistently infects most people, colonizing blood monocytes and shedding into saliva and other secretions. Infection frequently causes disease in the immunocompromised. It causes particular problems in pregnancy: approximately 1 % of neonates are infected; 10-20 % of these show obvious harm; and primary infection in pregnancy carries a >50 % risk of permanent infant disability [1] . There seem not to be especially virulent HCMV strains, nor a particular susceptibility to placental infection in the mothers of affected children, as one episode of congenital disease rarely predicts further episodes. Probably the main driver of disease is systemic viral load. While drugs such as ganciclovir can limit HCMV replication, the generally mild, non-specific symptoms of acute adult infection make diagnosis difficult. Toxicity also limits the opportunities for drug treatment. Prophylactic vaccination would be preferable. Unfortunately, the vaccine strategies tried so far have shown only modest efficacy [2] .
HCMV host entry
One possible vaccine target is virion entry. Which mucosal surface must be protected? Genital transmission is possible [3] , but probably most infections are acquired from saliva shed by acutely or chronically infected carriers. Communal childcare is a common transmission setting. HCMV is hypothesized to enter new hosts orally, because it is also found in breast milk and breast feeding from carrier mothers increases infection [4] . However, breast feeding entails generally close mother/infant contact, and while most milk is swallowed, it also routinely contaminates the upper respiratory tract. No oral target cell has been identified, and controlled oral inoculations have not been shown to infect. Therefore oral entry is unproven. Viral evolution is driven by transmission efficiency. Primary infection is a significant source of HCMV transmission [5] , so HCMV strains must compete to first enter new hosts. Any gain in virion capture or shedding should promote this and be selected. Efficient salivary shedding means efficient virion release into saliva. Oral entry would imply selection for efficient virion capture from saliva. How can both operate? Acute epidemic viruses can promote shedding by extensive epithelial destruction, but most HCMV shedding is asymptomatic. Entry further down the gastrointestinal tract would solve the problem. However, virion exposure to gastric acid -milk only transiently raises the gastric pH [6] -as well as to proteases and bile would severely reduce infection. If the stomach were an important entry route, HCMV would surely have evolved acid, protease and bile resistance. As it has not, non-oral entry routes need to be considered. It has been argued that HCMV transmission is inefficient [7] . As viruses are selected for efficient transmission, this seems unlikely. Oral virion uptake may be inefficient, but that does not mean transmission is inefficient. The conclusion was based on the detection of transient, weak PCR signals from saliva and the assumption that these reflected viral replication in the oral mucosa. It will be important to support this conclusion with other assays.
HCMV systemic spread A vaccine targeting only host entry might postpone primary HCMV infection without reducing its systemic spread. If delivered in infancy, this might even increase congenital harm by delaying infection and so increasing the risk of primary infection in pregnancy. Therefore systemic spread, which provides access to the placenta, is another important target. Infected blood monocytes [8, 9] seem a likely vehicle. They are hypothesized to derive from latently infected haematopoietic stem cells (HSCs) [10] . This would imply prior spread to the bone marrow. Such spread might also reach the placenta. Therefore it is important to consider how HCMV first reaches systemic sites.
Learning from other CMVs
The difficulty of analysing early human infections makes other animals a vital source of information. HCMV functions poorly in non-humans, and infecting human tissues transplanted into mice [11] is unable to mimic normal host colonization and spread. However, the natural CMVs of experimentally accessible mammals can be analysed. Their genetic relatedness roughly matches that of their hosts, consistent with herpesviruses evolving predominantly by cospeciation [12] . Functional similarity is harder to assess. Mammalian colonization by CMVs clearly preceded primate/rodent divergence [13] . How much change is likely since? Viral evolution is driven by the host: at steady state there is little or no selection for viral change, but host changes that reduce transmission should select compensatory viral changes. Thus, viral evolution should reduce any impact of host divergence on infection outcomes.
Immune evasion provides an example. Mouse and human immune genes, despite fulfilling equivalent functions, show marked genetic divergence, and many MCMV and HCMV immune evasion genes appear to have evolved independently [14] . The common outcome is blunted immune function. Such convergent evolution is unlikely to be limited to immune evasion. For example, mammals share a basic ontogeny and organization of monocytes [15] , so CMV interactions with them should also be broadly similar. Our 'hygienic' lifestyle in the developed world has possibly reduced or delayed HCMV infection [16] . However, its adoption is very recent, and how it will drive viral evolution is still unclear.
Experimentally accessible CMVs include those of rhesus macaques (RhCMV), mice (MCMV), rats (RCMV) and guinea pigs (GPCMV). Of these, RhCMV [17] is genetically closest to HCMV, as humans diverged from rodents 75 million years ago and from macaques 25 million years ago. GPCMV can infect the foetus [18] , and so can help us to understand viral transport across the placenta. However, investment in mice as the main experimental model of human biology makes MCMV probably the best suited to understanding how normal infection works.
MCMV host entry HCMV transmits well in day-care settings [19] , so analysis of MCMV entry has focused on pups. Experimental inoculation technique is crucial [20] . For example, strong early lung signals in a report of MCMV infection by gavage [21] suggested respiratory tract contamination. Infected gastrointestinal cells were not identified, and other studies [22, 23] have found no infection by oral MCMV. Experimental RhCMV infection uses oral inoculation. However, the macaques are anaesthetized [24] . Even brief anaesthesia of mice routinely results in oral MCMV being aspirated [25] . Identifying natural entry routes needs alert subjects, low inoculation volumes, and direct identification of infected cells.
We tracked MCMV entry into alert mice by imaging virusexpressed luciferase [23] , building on similar analyses of murid herpesvirus-4 (MuHV-4) [25] and herpes simplex virus-1 (HSV-1) [26] . Lightly restrained mice were given virus in 1-5 µl droplets, either orally or nasally. Live imaging then provided comprehensive, unbiased sampling, without the contamination problems of dissection and PCR. Nasal virus resulted in infection and oral virus did not. Although mice swallow most of even a 1 µl inhaled droplet [20] , acute infection was confined to the upper respiratory tract. Oral inoculation occasionally infected 1-2-day-old pups, but their luciferase signals were nasal, implying inoculum aspiration. Breast-feeding alone was insufficient for MCMV transmission, but when mice were provided with materials to make nests, there was transmission between pups, from adults to pups and from pups to adults [23] . Early adult infection during natural transmission was not identified, but early pup infection was nasal.
Tracking replication-deficient MCMV showed that inhaled virions directly infect olfactory neurons [23] . Combined oral/nasal inoculation of neonatal mice with a locally isolated MCMV strain additionally identified infection of the nasal-associated lymphoid tissue [27] . However, this was after 5 days, so as nasal secretions pass over the nasal-associated lymphoid tissue, primary infection was not clearly distinguished from secondary spread. In our hands, inhaled replication-deficient MCMV does not significantly infect the nasal-associated lymphoid tissue.
MuHV-4 [25] and HSV-1 [26] also enter mice via the olfactory epithelium. Conservation across such diverse herpesviruses implies that olfactory entry predates mammalian speciation. What are the key molecular events? In natural transmission settings, the decision point is virion capture. If capture were not sufficiently avid, then the evolution of downstream events in virus entry would not have occurred.
(Unnatural infections provide no such guarantee as they have not driven viral evolution.) Olfactory MuHV-4 capture depends on heparan binding [25] , a near-universal property of mammalian herpesviruses -including HCMV [28] . Its contribution to infection is only unclear for Epstein-Barr virus [29] , for which the standard virus strains and cell lines do not reproduce efficient epithelial infection [30] . Most transformed epithelial cells express abundant heparan. However, differentiated epithelial cells lose expression, so most in vivo epithelia -including those of the oropharynxonly have basal heparan, which is inaccessible to incoming (or shed) virions [25, 31] . The olfactory epithelium provides a striking exception, as heparan is expressed on the apical cilia of olfactory neurons. Epithelial damage can reveal basal heparan and may explain genital MuHV-4 transmission during mating [32] . In other settings epithelial damage seems to be an unlikely basis for efficient transmission. Thus we hypothesize that many heparan-binding viruses enter via olfactory neurons (Fig. 1) .
MCMV systemic spread
Intraperitoneally (i.p.) injected MCMV reaches blood monocytes [33] . However i.p. inocula directly reach sinuslining macrophages in the liver and spleen, as well as peritoneal macrophages [34] [35] [36] , so this cell-associated viraemia might not match that of natural infection. Subcutaneous (s.c.) MCMV also spreads via monocytes [37] . It was hypothesized to penetrate blood vessels and reach patrolling monocytes. Yet vascular infection was not visualized, and the underlying assumption that CX3CR1 provides a lineage marker of patrolling monocytes is questionable [38] . Futhermore, s.c. MCMV disseminates via LNs, where its main target is subcapsular sinus macrophages [39, 40] .
Identifying olfactory host entry has provided new insights into MCMV spread. In BALB/c pups given luciferase-tagged MCMV strain K181, infection remains localized to the nose for several days, with surprisingly little evidence of viral replication. It then appears in many sites. We envisage that secondary infection sites are more productive than the nose, so once they are seeded there is rapid further spread. Spread from the nose is associated with myeloid cells infiltrating the olfactory epithelium, becoming infected, and then appearing in luciferase + secondary sites [23] . Acute luciferase signals in the olfactory-draining superficial cervical LNs of some pups suggest that they provide access to the blood. Adult olfactory infection spreads less dramatically, but again involves the cervical LNs. Acute systemic signals lack a consistent focus, often coming from muscle or subcutaneous tissue. Unlike after i.p. inoculations, the liver and spleen are not prominent targets. Rather, the salivary glands become the main focus of infection, and luciferase signals remain detectable here for several weeks.
MCMV spreads via dendritic cells (DCs)
The variable lag before olfactory MCMV starts to spread, and the rapidity with which spread then proceeds, make intermediate events hard to capture.
Lung infection also spreads via LNs but shows more primary virus replication and follows more predictable kinetics. Thus it allows more detailed analysis. The main cell types infected in the lungs are DC-type CD11c + myeloid cells, macrophage-type CD11c À myeloid cells, and type II alveolar epithelial cells [41] . Almost all infected cells in draining LNs, blood and acutely colonized salivary glands are CD11c + , and floxed virus tagging in CD11c-cre mice confirms a central role for CD11c + cells in spread [36] . Replication-deficient MCMV delivered into the lungs also reaches the salivary glands in CD11c + cells. Therefore, DCs infected in the lungs migrate through LNs and the blood to other tissues. DC traffic to LNs is well recognized, but they have been assumed then to die [42] as the efferent lymph contains few myeloid cells [43] . MCMV-infected DCs instead leave LNs via high endothelial venules (HEVs) [36] (Fig. 2) . This was surprising as naive lymphocytes enter LNs via HEVs, but DCs normally migrate towards HEVs for antigen presentation [44] , and it explains how large numbers of myeloid cells can enter LNs and then disappear without obviously dying in situ or appearing in efferent lymph.
A key role for viral GPCRs in MCMV spread
MCMVs carrying knockouts of genes important for DC migration should maintain infection in primary sites, such as the lungs after nasal inoculation, but exhibit reduced replication it in secondary sites, such as the salivary glands. This phenotype is observed for disruption of MCMV M33 [45] . Disrupting the homologous GPCR of RCMV (R33) also reduces salivary gland infection [46] suggesting conservation of function. These UL33 family GCPRs are homologous to host CC chemokine receptors [47] . However, unlike the chemokine receptors they signal constitutively [48] [49] [50] . This is essential for MCMV spread to the salivary glands [51] . i.p. M33
À MCMV still reaches the liver and spleen [52] , but such inoculations deliver cell-free virions directly to these organs via the thoracic duct, blood and fenestrated capillaries. The idea that M33 promotes MCMV replication in, rather than spread to, the salivary glands [53] was similarly based on non-physiological inoculations that open up new, M33-independent routes of spread.
The MCMV M78 GPCR, again conserved in HCMV, is also important for salivary gland infection [54, 55] . M78 homologues retain the seven-transmembrane GPCR organization, but are only distantly related to chemokine receptors and lack constitutive signalling [50] . M78 has acquired a new function of degrading MHC class II [55] .
Old World primate CMVs have additional US28 family GPCRs, two in HCMV -US27 and US28 -and five in RhCMV [56] . US28, the most studied, is both constitutively active and able to bind a broad spectrum of chemokines [57, 58] . In vitro studies have suggested roles in immune evasion, cell mobilization [59] , metabolic programming [60] , virus dissemination [61] and latency regulation [62] . US28 is also reported to influence vascular disease, cancer and HIV replication [63, 64] . Thus it has interest as a therapeutic target [65] . However, the strong context dependence of GPCR signalling can make experimental data difficult to extrapolate to natural infection. Humanized mice allow in vivo analysis [66] but do not reproduce the normal cellular interactions essential for investigating virus spread. Viral GPCRs can engage multiple G proteins, with likely cell type specificity [50] . Potential cross-talk with cellular GPCRs, through heterodimerization or downstream target modulation, adds further complexity [67, 68] . Thus, it is essential to analyse natural infections. This can be done with M33, which shows similar constitutive signalling to US28 [50] .
Nasally acquired M33
À MCMV infects lungs and LNs similarly to the wild-type, but further spread is globally impaired (Fig. 3) . This is because M33 is required for infected DCs to pass from LNs to the blood [36] . M33 + -infected DCs are sparse in LNs, suggesting that they exit rapidly, and most are seen inside or closely associated with HEVs. By contrast, M33 À -infected DC are numerous in LNs, suggesting accumulation, and most are in the LN parenchyma. An M33 point mutant lacking Gq signalling matches the complete knockout. Therefore, M33 signalling promotes infected DC exit from LNs via HEVs. Substituting US28 for M33 preserves infected DC egress from LNs via HEVs, while signalling-deficient U28 is ineffective [69] . This result suggests that HCMV-infected DCs may also reach the blood by recirculation, after being infected in peripheral tissues.
Host contributions to infected DC migration
Because M33 signals constitutively, it can licence DCs to move but cannot tell them where to move: this requires tissue cues, such as adhesion ligands or chemokines, and so host-defined paths. In the lungs MCMV infects both DCs and phagocytic myeloid cells, but only infected DCs reach LNs [36] . Therefore virus-driven migration is not indiscriminate, but correlates with normal cell function. Murine blood monocytes are divided into Ly6C hi CCR2 + CX3CR1 int (inflammatory) and Ly6C lo CCR2 À CX3CR1 hi (patrolling intravascular) subsets [70] . Inflammatory monocytes can extravasate and become DCs. Therefore, we envisage that they, or tissue-resident DCs, give rise to recirculating infected cells. HCMV targets the equivalent CD14 hi subset of human monocytes [10] .
DC recirculation was previously unknown, so its host signals are unexplored. T cell recirculation provides possible clues. Naive T cells reach LNs via HEVs and extravasated memory T cells do so via afferent lymph [71] . Both depend on CCR7 [72] , which also guides DCs to the T cell area of LNs [73] . Its ligands, CCL19 and CCL21, are produced by lymphatic endothelium and LN fibroblastic reticular cells. Agonist-induced receptor downregulation is a common theme in chemokine signalling, and CCR7 down-regulation promotes T cell exit from LNs [74] . Therefore, constitutive M33/US28 signalling might promote LN egress by downregulating CCR7-type retention signals. Sphingosine 1-phosphate (S1P) also guides T cells out of LNs [75] . It is produced in the blood and broken down in LNs by S1P lyase, creating a gradient. Signalling through S1PR1 promotes T cell egress from LNs via efferent lymphatics. DCs express multiple S1P receptors. Therefore S1P pathway engagement might help infected DCs to leave LNs.
Infected DC extravasation M33 deficiency reduces MCMV seeding to the salivary glands more severely than it reduces acute viraemia [36] , and while US28 rescues LN egress by M33 À MCMV, it does not rescue infected DC extravasation into the salivary glands [69] . Therefore, the latter is a second M33 function. HCMV-infected DCs presumably also extravasate, but US28 may lack this function or be species-restricted. We envisage that M33 and US28 promote DC exit from LNs by overcoming inflammatory retention signals [76] , and that DCs normally recycle back to the blood only when inflammation subsides. DC extravasation is contrastingly driven by inflammation, and constitutive M33 signalling alone seems unlikely to substitute, as that of US28 is ineffective. Instead, M33 may heterodimerize with host GPCRs or bind host ligands. These pathways remain to be defined.
A new CMV infection model
The capacity of DCs both to initiate tissue infections and to collect virus from tissues for redistribution suggests a new model of CMV host colonization (Fig. 4) . The key role of DCs is virus transport: from the entry site to other tissues, between tissues, and to shedding sites for exit. We envisage that most viral genomes are latent in tissue stromal cells, having been seeded there by DCs. Reactivation then infects more DCs, which again recirculate. Thus, DC infection turns over rapidly, and is constantly replenished by reactivating stromal cells. The relatively prolonged in vitro latency of HCMV in monocytes may reflect a loss of extravasation-linked reactivation signals. Constant infection turnover would explain the large long-term immune responses CMVs can elicit in immunocompetent hosts, and the diversity of disease sites in immunocompromised hosts. Outstanding questions are how fast tissue reservoirs turn over, that is how vulnerable are they to anti-viral drugs, and whether long-term viral loads depend more on acute primary spread, which might be reduced by vaccination, or on the intrinsic productivity of lytic replication in a given host. DC recirculation explains how MCMV can colonize blood monocytes without infecting HSCs [77] . US28 driving DC egress from LNs suggests that HCMV might also use this route. It does not disprove HSC infection: potentially, HCMV could use DC recirculation to reach systemic sites, then switch to HSC infection. However, if HSCs are the main long-term reservoir, it is unclear why solid organ transplants transfer HCMV more readily than HSC transplants [78, 79] . The capacity of lytic cycle inhibitors to reduce blood monocyte infection rapidly [80] would also better fit the lytic reseeding model, as the derivation of latently infected blood monocytes from latently infected HSCs should be unaffected. In addition, chronic lytic exchange between non-dividing cells would explain why CMVs apparently lack an episome maintenance functionwhich latent g-herpesviruses need to survive in dividing cells.
The infected HSC hypothesis was based on infection in vitro [81] , which has been studied extensively since [82] . Myeloid infection has also been achieved by i.p. delivery of HCMVinfected fibroblasts into immunodeficient, G-CSF-treated mice transplanted with human bone marrow [83] , and by injecting immunodeficient mice with peripheral blood cells from G-CSF-treated HCMV + human donors [84] . These results establish that HCMV can infect HSCs. Whether it normally does so is less clear. Even in homologous hosts, the inoculation route dramatically affects herpesvirus infection profiles [85, 86] . MuHV-4 readily infects cells in the brain if delivered there, but it does not normally reach them [87] . HCMV DNA has been detected by PCR of flow cytometrically enriched CD34 + cells from bone marrow of carriers [88] . Yet the levels are low and not all samples are positive, leading others to question whether HSCs are a normal site of persistence [89] . The difficulty of detecting stem cell infection contrasts with the relative ease of detecting peripheral monocyte infection [90] ; complete exclusion of viral DNA from immigrant monocytes in bone marrow samples is hard to guarantee; and CD34 expression is not limited to HSC [91] . Infected HSCs have not been visualized in bone marrow biopsies or recovered for clonal propagation. Therefore, more direct analysis of natural infection is needed. DC recirculation explains how CMVs can reach systemic sites after mucosal entry, and might also explain how they persist.
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